Cargando…

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA

OBJECTIVES: Psoriatic arthritis (PsA) phenotypes are typically defined by their clinical components, which may not reflect patients’ overlapping symptoms. This post hoc analysis aimed to identify hypothesis-free PsA phenotype clusters using machine learning to analyse data from the phase III DISCOVE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richette, Pascal, Vis, Marijn, Ohrndorf, Sarah, Tillett, William, Ramírez, Julio, Neuhold, Marlies, van Speybroeck, Michel, Theander, Elke, Noel, Wim, Zimmermann, Miriam, Shawi, May, Kollmeier, Alexa, Zabotti, Alen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Psoriatic Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069583/ https://www.ncbi.nlm.nih.gov/pubmed/37001920 http://dx.doi.org/10.1136/rmdopen-2022-002934

Ejemplares similares

Treat-to-target in PsA: methods and necessity
por: Dures, Emma, et al.
Publicado: (2020)

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
por: Mease, Philip J, et al.
Publicado: (2018)

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
por: Regierer, Anne Constanze, et al.
Publicado: (2023)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
por: Gottlieb, Alice B, et al.
Publicado: (2023)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2022)

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
por: Ritchlin, Christopher T, et al.
Publicado: (2021)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
por: Coates, Laura C, et al.
Publicado: (2023)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
por: Gossec, Laure, et al.
Publicado: (2022)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
por: De Marco, Gabriele, et al.
Publicado: (2023)

Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis
por: Kasiem, Fazira R., et al.
Publicado: (2023)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia
por: Zabotti, Alen, et al.
Publicado: (2019)

Interleukin‐17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis
por: Xu, Xiaofei, et al.
Publicado: (2020)

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis
por: den Braanker, Hannah, et al.
Publicado: (2020)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis
por: Snoeck Henkemans, Selinde V J, et al.
Publicado: (2022)

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis
por: Wervers, Kim, et al.
Publicado: (2018)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis
por: Dubash, Sayam, et al.
Publicado: (2022)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
por: Mease, Philip J, et al.
Publicado: (2020)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
por: Ritchlin, Christopher T, et al.
Publicado: (2023)

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
por: Smolen, Josef S, et al.
Publicado: (2020)

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2020)

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries
por: Lucasson, Florian, et al.
Publicado: (2022)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
por: McGagh, Dylan, et al.
Publicado: (2020)

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
por: Mease, Philip J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_re92ututm926hlgje21oa52qpu